Arrowhead制药（Arrowhead Pharmaceuticals）在宣布启动股票公开发售及可转换债券发行计划后，其股价在盘前交易时段应声下跌3.4%。此次融资举措旨在为公司研发管线及一般企业用途筹集资金，但市场对此反应消极，显示出投资者可能担忧股权稀释风险。
Arrowhead制药（Arrowhead Pharmaceuticals）在宣布启动股票公开发售及可转换债券发行计划后，其股价在盘前交易时段应声下跌3.4%。此次融资举措旨在为公司研发管线及一般企业用途筹集资金，但市场对此反应消极，显示出投资者可能担忧股权稀释风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.